DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

Issue 01 · Volume 14 · January 1988 DOI: 10.1055/s-002-7731

  • 1
    Thomas, Duncan P.:

    Overview of Venous Thrombogenesis

  • 9
    Ofosu, Frederick A.; Gray, Elaine:

    Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties

  • 18
    Boneu, Bernard; Caranobe, Claudine; Cadroy, Yves; Dol, Frederique; Gabaig, Anne-Marie; Dupouy, Dominique; Sie, Pierre:

    Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit

  • 28
    Andrew, Maureen; Schmidt, Barbara:

    Use of Heparin in Newborn Infants

  • 33
    Buchanan, Michael R.:

    Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds

  • 41
    Turpie, Alexander G. G.:

    Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism

  • 50
    Fuster, Valentin; Badimon, Lina; Badimon, Juan J.; Chesebro, James:

    Prevention of Thromboembolism Induced by Prosthetic Heart Valves

  • 59
    Hornstra, Gerard:

    Effect of Dietary Lipids on Arterial Thrombus Formation: Rationale for the Support of Drug Therapy by Diet

  • 66
    Bastida, Eva:

    The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis

  • 73
    D'Amore, Patricia A.:

    Antiangiogenesis as a Strategy for Antimetastasis

  • 79
    Talmadge, James E.; Black, Paul L.:

    Immunotherapy of Metastatic Disease

  • 88
    Rickles, Frederick R.; Hancock, Wayne W.; Edwards, Richard L.; Zacharski, Leo R.:

    Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulants and/or Antiplatelet Drugs in Cancer Treatment

  • 95
    Collen, Desire:

    Potential Approaches for Therapeutic Intervention of Thrombosis by Fibrinolytic Agents

  • 100
    Loskutoff, David J.:

    Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy

  • 110
    Gurewich, Victor:

    Pro-Urokinase: Physiochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of Action

  • 116
    Levine, Mark N.; Hirsh, Jack:

    Clinical Use of Low Molecular Weight Heparins and Heparinoids

  • 126
    Rickles, Frederick R.; Hancock, Wayne W.:

    Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions

  • 133
    Murano, Genesio; Bick, Rodger L.:

    Abstracts of Current Literature